Home Cart Sign in  
Chemical Structure| 1799631-75-6 Chemical Structure| 1799631-75-6

Structure of MIK665
CAS No.: 1799631-75-6

Chemical Structure| 1799631-75-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MIK665 is an inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities.

Synonyms: S-64315

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MIK665

CAS No. :1799631-75-6
Formula : C47H44ClFN6O6S
M.W : 875.41
SMILES Code : O=C(O)[C@H](OC1=C(C(C2=CC=C(OCCN3CCN(C)CC3)C(Cl)=C2C)=C(C4=CC=C(F)C=C4)S5)C5=NC=N1)CC6=CC=CC=C6OCC7=NC(C8=CC=CC=C8OC)=NC=C7
Synonyms :
S-64315
MDL No. :MFCD32669779

Safety of MIK665

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03672695 Acute Myeloid Leukaemia Phase 1 Not yet recruiting March 31, 2022 United States, Connecticut ... More >> Smilow Cancer Hospital at Yale Not yet recruiting New Haven, Connecticut, United States, 06511 United States, Texas The University of Texas MD Anderson Cancer Center, Houston, TX Not yet recruiting Houston, Texas, United States, 77030 Australia Peter MacCallum cancer centrer Not yet recruiting Melbourne, Australia The Alfred Hospital Department of Haematology Not yet recruiting Victoria Park, Australia France Institut Paoli-Calmettes Not yet recruiting Marseille, France Hopital Saint-Antoine Not yet recruiting Paris, France Institut Universitaire du Cancer Toulouse - Oncopole Not yet recruiting Toulouse, France Less <<
NCT02979366 Acute Myeloid Leukaemia (AML) ... More >> Myelodysplastic Syndrome (MDS) Less << Phase 1 Recruiting October 2020 United States, Connecticut ... More >> Patient Care Location: Smilow Cancer Hospital at Yale Recruiting New Haven, Connecticut, United States, 06511 United States, Texas The University of Texas MD Anderson Cancer Center, Department of Leukemia, Division of Cancer Medicine Recruiting Houston, Texas, United States, 77030 Australia The Alfred Hospital Department of Haematology Recruiting Melbourne, Australia, 3004 Royal Melbourne Hospital, Department of Clinical Haematology and BMT Service Recruiting Melbourne, Australia, 3050 France Institut Paoli-Calmettes Departement d'Hématologie Recruiting Marseille, France, 13009 Hôpital Saint-Antoine Département d'Hematologie Clinique et de Thérapie cellulaire Recruiting Paris, France, 75012 Spain Hospital Universitario Vall d' Hebron/VHIO Hematology Department Recruiting Barcelona, Spain, 08035 Hospital Universitario La Fe Hematology Department Recruiting Valencia, Spain, 46026 Less <<
NCT02992483 Multiple Myeloma (MM), Lymphom... More >>a, Large B-Cell, Diffuse (DLBCL), Lymphoma Less << PHASE1 COMPLETED 2019-06-07 MD Anderson Cancer Center/Univ... More >>ersity of Texas MD Anderson CC, Houston, Texas, 77030, United States|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Fukuoka-city, Fukuoka, 811-1395, Japan|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.14mL

0.23mL

0.11mL

5.71mL

1.14mL

0.57mL

11.42mL

2.28mL

1.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories